World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
123
Citations
109527
World Ranking
3258
National Ranking
1798

Overview

Paolo A. Ascierto is affiliated with the National Institutes of Health in the United States and has contributed extensively to the field of oncology, with a focus on cancer immunotherapy and melanoma research. Their work spans various subfields, including oncology, molecular biology, immunology, epidemiology, and infectious diseases.

The scientist's research covers several key topics, such as:

  • Cancer Immunotherapy and Biomarkers
  • Melanoma and MAPK Pathways
  • CAR-T Cell Therapy Research
  • Cutaneous Melanoma Detection and Management
  • Immunotherapy and Immune Responses
  • Colorectal Cancer Treatments and Studies
  • Nonmelanoma Skin Cancer Studies

Frequent publication venues for Paolo A. Ascierto include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Journal for ImmunoTherapy of Cancer
  • Journal of Translational Medicine

Frequent coauthors collaborating with Paolo A. Ascierto include:

  • Georgina V. Long
  • Dirk Schadendorf
  • Caroline Robert
  • Piotr Rutkowski
  • Reinhard Dummer

Among their recent papers are:

  • "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events" (2021), Journal for ImmunoTherapy of Cancer
  • "Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial" (2020), The Lancet
  • "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma" (2022), Zurich Open Repository and Archive (University of Zurich)
  • "Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial" (2020), The Lancet Oncology
  • "Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer" (2020), Nature Communications

Paolo A. Ascierto's extensive publication record reflects a concentration on immune checkpoint inhibitors, melanoma treatment strategies, and immunotherapy response mechanisms. Their research integrates clinical trials and biomolecular investigations to advance understanding and treatment of advanced cancers.

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Nivolumab in previously untreated melanoma without BRAF mutation.

    Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

    Aurelien Marabelle;Dung T. Le;Paolo A. Ascierto;Anna Maria Di Giacomo

  • Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

    James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

    Franck Pagès;Bernhard Mlecnik;Florence Marliot;Gabriela Bindea;Gabriela Bindea;Gabriela Bindea

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

    Jérôme Galon;Jérôme Galon;Jérôme Galon;Bernhard Mlecnik;Bernhard Mlecnik;Bernhard Mlecnik;Gabriela Bindea;Gabriela Bindea;Gabriela Bindea;Helen K. Angell;Helen K. Angell;Helen K. Angell

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

    Paolo A Ascierto;Grant A McArthur;Grant A McArthur;Brigitte Dréno;Victoria Atkinson

  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

  • Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Reinhard Dummer;Paolo A Ascierto;Helen J Gogas;Ana Arance

Frequent Co-Authors

Gerardo Botti
Gerardo Botti Istituto Giannina Gaslini
Giuseppe Palmieri
Giuseppe Palmieri National Academies of Sciences, Engineering, and Medicine
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Caroline Robert
Caroline Robert University of Paris-Saclay
Georgina V. Long
Georgina V. Long University of Sydney
Michele Maio
Michele Maio University of Siena
Reinhard Dummer
Reinhard Dummer University of Zurich
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Claus Garbe
Claus Garbe University of Tübingen
Mario Mandalà
Mario Mandalà European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the field of Medicine in the USA doesn’t just mean becoming a doctor. There are a growing number of rewarding roles and degree programs that offer diverse career pathways. Many students are choosing online options, which often provide greater flexibility and cost savings.

Careers in hospital management and operational leadership are in high demand. You can start by pursuing healthcare administration degrees online, making it easier to study while gaining hands-on experience. For those aiming for advanced roles, there are cheapest mha programs that offer solid preparation for upper management in healthcare facilities.

Nursing professionals looking to enhance their expertise and impact might consider cheap online dnp programs, which open doors to leadership, research, and academic positions. Alternatively, those interested in pharmaceutical sciences can earn advanced credentials through online pharmd programs, expanding their scope to include clinical, consulting, and industry roles.

Online degrees in these areas can help you prepare for a meaningful career in healthcare, often at a lower price and with more flexible scheduling than traditional on-campus programs.

Best Scientists Citing Paolo A. Ascierto

Trending Scientists